TMDXHealthcare · Medical DevicesThe 13 Wall Street analysts covering TransMedics Group, Inc. hold a median 12-month price target of $100 — +37.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 4 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores TransMedics Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (85): The business earns solid, repeatable profits on what it owns.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TMDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +37.6% from it.
Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Canaccord Genuity | Maintains | Buy | $95 → $94 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $120 |
| 8 Sept 2026 | TD Cowen | Reiterates | Buy | — |
| 8 Sept 2026 | TD Cowen | Reiterates | Buy | $120 |
| 5 Aug 2026 | Piper Sandler | Reiterates | Overweight | $120 → $100 |
| 5 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 5 Aug 2026 | UBS | Maintains | Neutral | — |
| 5 Aug 2026 | UBS | Maintains | Neutral | $80 → $77 |
| 3 Aug 2026 | Needham | Maintains | Buy | $142 → $106 |
| 3 Aug 2026 | Needham | Maintains | Buy | — |
| 28 July 2026 | UBS | Initiates | Neutral | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $100 → $90 |
| 1 July 2026 | TD Cowen | Reiterates | Buy | $120 |
| 1 July 2026 | TD Cowen | Reiterates | Buy | — |
| 30 June 2026 | Canaccord Genuity | Maintains | Buy | $124 |
| 30 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 18 June 2026 | Stifel | Maintains | Hold | — |
| 26 May 2026 | Stifel | Maintains | Hold | — |
| 6 May 2026 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TMDX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, TransMedics Group, Inc. returned −40.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 42% of US stocks
Cheaper than 34% of US stocks
Cheaper than 21% of US stocks
Cheaper than 11% of US stocks
Higher than 70% of US stocks
Higher than 9% of US stocks
Higher than 73% of US stocks
Higher than 68% of US stocks
Higher than 84% of US stocks
Higher than 90% of US stocks
Higher than 73% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TransMedics Group, Inc. has a market value of $2.3B and an enterprise value of $2.7B.
Revenue in the twelve months to 30 June 2026: $668.5M. The latest quarter grew 20.7% year on year.
Net income over the same four quarters: $151.7M, a 22.7% net margin.
Diluted earnings per share, trailing twelve months: $3.89.
Free cash flow in the twelve months to 30 June 2026: $79.0M.
Trailing P/E: 17.4×; forward P/E: 29.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
TransMedics Group, Inc. employs 898 people — $744K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TransMedics Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article highlights TransMedics’ OCS technology, pipeline and global expansion as growth supports, while noting margin pressures and rising investments as concerns.
Why it matters — These competing factors offer TMDX watchers a concise view of the growth opportunities and operating challenges discussed in the item.
Zacks Investment Research examines analyst projections for TransMedics’ key metrics for the quarter ended September 2026, beyond forecasts for revenue and earnings.
Why it matters — The metric estimates provide TMDX watchers additional context on expectations for the quarter.
Business Wire reported that SBS Law is offering TMDX investors an opportunity to join a fraud investigation involving TransMedics Group, Inc.
Why it matters — TMDX investors may want to note the reported investigation involving the company.
TransMedics announced inducement grants on October 28, 2026, consisting of non-qualified stock options for 71,815 shares and 47,924 restricted stock units awarded to nine employees.
Why it matters — The grants are a disclosed equity-compensation item for TMDX, with the announcement made under Nasdaq Listing Rule 5635(c)(4).
TransMedics announced that it will participate in three upcoming investor conferences.
Why it matters — TMDX watchers may note the company’s upcoming investor-conference participation.
The 13 Wall Street analysts covering TransMedics Group, Inc. have a median 12-month price target of $100, with estimates ranging from $65 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering TransMedics Group, Inc., 9 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TransMedics Group, Inc. 40 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, TransMedics Group, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (85 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +37.6% from the last close, and Ticker Nerd's factor model ranks TransMedics Group, Inc. 40 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering TransMedics Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $125 over the next 12 months.
TransMedics Group, Inc. returned -40.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
TransMedics Group, Inc. is a commercial-stage medical technology company focused on organ transplant therapy.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Reasons to Retain TransMedics Stock in Your Portfolio for Now". The article highlights TransMedics’ OCS technology, pipeline and global expansion as growth supports, while noting margin pressures and rising investments as concerns.
TransMedics Group, Inc. is a commercial-stage medical technology company focused on organ transplant therapy. The company develops and commercializes the Organ Care System (OCS), a platform designed to preserve, monitor, and assess donor organs outside the human body in conditions that more closely resemble a living environment. Its current portfolio supports heart, lung, and liver transplantation, helping transplant teams manage donor organs more effectively than traditional cold storage methods. TransMedics also provides related disposables and service offerings that support organ transport, preservation, and clinical workflow in the transplant process. Headquartered in Andover, Massachusetts, TransMedics Group, Inc. serves a specialized role in healthcare by addressing the needs of patients with end-stage organ failure and supporting hospitals, transplant centers, and organ recovery organizations across its markets.
CEO Dr. Waleed H. Hassanein M.D. · 898 employees · United States · https://www.transmedics.com
